After reading this note you will be able to recognise the clinical picture of hepatorenal syndrome, list the key precipitating factors seen in Kenya, interpret the essential investigations, grade severity and outline the immediate and definitive management steps – remembering to verify drug choices and local protocols against the Kenya MoH guideline and your hospital formulary.
Definition
Hepatorenal syndrome (HRS) is a functional, rapidly progressive renal failure that occurs in patients with advanced chronic liver disease (usually cirrhosis) or acute severe liver injury, in the absence of intrinsic kidney pathology. It is characterised by marked reduction in glomerular filtration rate (GFR) that is reversible if the underlying hepatic circulatory dysfunction is corrected.
Anatomy and physiology you need
| Structure | Relevance to HRS |
|---|---|
| Liver sinusoids | Portal hypertension → splanchnic vasodilation |
| Splanchnic arterial bed | Excess nitric oxide production → systemic vasodilation |
| Renal afferent arterioles | Intense vasoconstriction mediated by sympathetic activation, RAAS, endothelin |
| Circulating plasma volume | Effective arterial hypovolemia despite total fluid overload |
| Nephron (glomerulus) | Filtration falls because of reduced renal perfusion pressure |
| Lymphatic drainage of abdomen | Ascites contributes to intra‑abdominal pressure, further impairing renal blood flow |
Understanding that the kidney itself is structurally intact is essential; the failure is driven by haemodynamic derangement secondary to severe liver disease.
Causes and risk factors
Liver‑related precipitating factors
- Decompensated cirrhosis (alcoholic, viral hepatitis B/C, non‑alcoholic steatohepatitis)
- Acute‑on‑chronic liver failure (e.g., super‑infection, drug‑induced injury)
Common precipitants in the Kenyan context
| Factor | Why it matters locally |
|---|---|
| Spontaneous bacterial peritonitis (SBP) | High prevalence of ascites and limited early presentation |
| Large volume paracentesis without albumin replacement | Common practice in resource‑limited settings |
| Gastrointestinal bleeding | Hepatitis B/C and schistosomiasis increase portal hypertension |
| Diuretic over‑use (furosemide, spironolactone) | Often prescribed empirically for ascites |
| Infections: HIV, TB, malaria, bacterial sepsis | All can precipitate systemic vasodilation and renal hypoperfusion |
| Rheumatic fever with cardiorenal involvement | Rare but reported in rural clinics |
| Sickle cell disease crises | Vaso‑occlusion can worsen hepatic congestion and renal flow |
| Hepatotoxic herbal remedies | Unregulated use leads to acute liver injury |
Pathophysiology
- Advanced liver disease → portal hypertension → massive splanchnic vasodilation (↑ NO, prostacyclin)
- Systemic arterial under‑filling despite total fluid excess → activation of baroreceptor reflex
- Neuro‑humoral response: ↑ sympathetic tone, ↑ renin‑angiotensin‑aldosterone system, ↑ antidiuretic hormone → intense renal vasoconstriction
- Reduced renal perfusion pressure → ↓ glomerular filtration → functional renal failure
- Feedback loop: worsening renal sodium and water retention → ascites expansion → further intra‑abdominal pressure → additional renal hypoperfusion
(Arrows: Liver disease → splanchnic vasodilation → effective hypovolemia → neuro‑humoral activation → renal vasoconstriction → ↓ GFR → HRS)
End of part 1.
Clinical features
History – what to ask
| Domain | Key questions | Rationale |
|---|---|---|
| Liver disease | “When was your liver disease diagnosed? What complications have you had (ascites, variceal bleed, encephalopathy)?” | Establish chronic liver disease and its decompensation – prerequisite for HRS. |
| Ascites & diuretics | “How much fluid have you been retaining? Have you been on spironolactone, furosemide or other diuretics? Any recent dose changes?” | Over‑diuresis precipitates renal hypoperfusion; recent diuretic escalation is a common trigger. |
| Infections | “Any recent fever, cough, dysuria, abdominal pain, skin sores, or recent hospitalisation? Have you been treated for TB, malaria or HIV‑related infections?” | Bacterial infection, spontaneous bacterial peritonitis (SBP), TB peritonitis, malaria or HIV‑related sepsis are frequent precipitants in our setting. |
| Gastro‑intestinal bleeding | “Any vomiting of blood or black stools? Any recent endoscopy?” | Acute variceal bleed causes massive vasodilation and renal vasoconstriction. |
| Medications & nephrotoxins | “Use of NSAIDs, aminoglycosides, contrast studies, herbal remedies?” | Direct renal insults must be excluded; NSAIDs blunt prostaglandin‑mediated renal vasodilation. |
| Volume status | “Do you feel thirsty? Any swelling of legs or abdomen? Any recent diarrhoea or vomiting?” | Helps differentiate hypovolaemia from true HRS. |
| HIV / TB / malaria | “Are you HIV positive? On antiretroviral therapy? Any recent TB treatment or malaria episodes?” | These infections can cause both liver injury and renal dysfunction, mimicking HRS. |
| Sickle cell / rheumatic disease | “Do you have sickle cell disease or a history of rheumatic fever?” | Sickle cell nephropathy or immune‑complex GN can present similarly. |
| Baseline renal function | “Have you ever had kidney disease? Any prior creatinine values?” | Excludes chronic kidney disease as primary cause. |
Examination – what to look for and why
| Finding | Interpretation |
|---|---|
| General – cachexia, spider nevi, palmar erythema | Reflect chronic liver disease severity. |
| Mental status – asterixis, confusion | May indicate hepatic encephalopathy; altered neuro‑hormonal balance contributes to renal vasoconstriction. |
| Jaundice – scleral icterus, skin | Confirms cholestasis or hepatocellular injury; severe jaundice correlates with poor hepatic reserve. |
| Ascites – shifting dullness, fluid wave | Presence of large-volume ascites is a major risk factor; intra‑abdominal pressure can impair renal perfusion. |
| Peripheral edema – pitting edema of lower limbs | May be due to hypo‑albuminemia or renal sodium retention; helps gauge volume status. |
| Blood pressure – low systolic (<100 mmHg) or narrow pulse pressure | Indicates systemic vasodilation and effective hypovolaemia driving renal vasoconstriction. |
| Heart rate – tachycardia | Compensatory response to low arterial filling. |
| Peripheral pulses – weak, delayed capillary refill | Sign of reduced peripheral perfusion. |
| Skin – cool, clammy | Reflects peripheral vasoconstriction secondary to neuro‑hormonal activation. |
| Abdominal exam – tender hepatomegaly, splenomegaly | Suggests portal hypertension and advanced disease. |
| Signs of infection – fever, localized tenderness, murmur | Identify precipitating sepsis or SBP. |
| Urine output – oliguria (<0.5 mL/kg/h) despite adequate fluid intake | Core clinical hallmark of HRS. |
Differential diagnosis
| Condition | Points toward it | How to separate from HRS |
|---|---|---|
| Acute tubular necrosis (ATN) | Recent nephrotoxin, hypotension, granular casts | Urine microscopy shows epithelial casts; FeNa >2 % |
| Prerenal azotemia (hypovolaemia) | Diarrhoea, vomiting, over‑diuresis, low CVP | FeNa <1 %, BUN/Cr >20, rapid rise in creatinine after fluid loss |
| Hepatorenal syndrome – type 1 | Rapid creatinine rise, advanced cirrhosis, precipitating infection | No intrinsic renal pathology, FeNa <1 %, no casts |
| Hepatorenal syndrome – type 2 | Slow progressive renal decline, refractory ascites | Same labs as type 1 but slower trajectory |
| Chronic kidney disease (CKD) | Prior abnormal creatinine, proteinuria, hypertension | Persistent structural changes on imaging, abnormal urine protein |
| Glomerulonephritis (e.g., lupus, post‑infectious) | Rash, arthralgia, hematuria, low complement | Positive serology, active urinary sediment |
| HIV‑associated nephropathy | HIV positivity, proteinuria, enlarged kidneys | HIV serology, renal biopsy if needed |
| Malaria‑related renal failure | Recent malaria episode, hemolysis, jaundice | Positive malaria smear, hemoglobinuria |
| Sickle cell nephropathy | Known sickle cell disease, hematuria, papillary necrosis | Sickle cell screen, characteristic imaging |
Investigations
| Test | What it answers | Typical result in HRS |
|---|---|---|
| Serum creatinine & urea | Baseline renal function, trend | Rising creatinine, BUN/Cr <20 |
| Electrolytes (Na⁺, K⁺) | Volume status, renal handling | Hyponatraemia, normal‑high K⁺ |
| Liver panel (AST, ALT, ALP, GGT, bilirubin) | Severity of hepatic injury | Elevated bilirubin, variable transaminases |
| INR / PT | Synthetic liver function | Prolonged INR |
| Complete blood count | Infection, anemia | Leukocytosis if infection, anemia of chronic disease |
| Urinalysis & microscopy | Intrinsic renal disease | Bland urine, no casts, low Na⁺ (<10 mmol/L) |
| Fractional excretion of sodium (FeNa) | Prerenal vs intrinsic | <1 % (prerenal pattern) |
| Urine sodium concentration | Same as FeNa | <10 mmol/L |
| Ascitic fluid analysis (if ascites) | SBP screening | PMN >250 cells/µL suggests SBP |
| Blood cultures | Sepsis source | Positive in septic precipitant |
| Imaging – renal ultrasound | Structural kidney disease | Normal size, no obstruction |
| Doppler hepatic ultrasound | Portal hypertension severity | High portal pressure, reversed flow |
| Serum albumin | Oncotic pressure | Low albumin |
| HIV, hepatitis B/C serology | Underlying infection | Positive if relevant |
| Malaria rapid test / thick smear | Recent malaria | Positive if malaria precipitant |
Diagnosis and severity
Diagnostic criteria (adapted to our setting)
- Advanced chronic liver disease (cirrhosis, Child‑Pugh B/C) with portal hypertension.
- Serum creatinine >1.5 mg/dL (or rise >0.3 mg/dL in 48 h) not explained by other renal pathology.
- Absence of shock and no current use of nephrotoxic drugs.
- No improvement after at least 48 h of diuretic withdrawal and plasma volume expansion with albumin (1 g/kg up to 100 g).
- Urine analysis showing low sodium (<10 mmol/L), FeNa <1 %, and no granular or epithelial casts.
If all are met → Hepatorenal syndrome.
Severity grading (clinical practice)
| Grade | Creatinine (mg/dL) | Clinical picture | Management implication |
|---|---|---|---|
| Type 1 (rapid) | >2.5 or ≥50 % rise within ≤2 weeks | Sudden oliguria, high mortality | Urgent vasoconstrictor therapy, early transplant referral |
| Type 2 (slow) | 1.5–2.5, progressive over weeks | Refractory ascites, modest renal decline | Long‑term albumin + vasoconstrictor, consider TIPS |
| Very severe | >4.0 | Marked encephalopathy, hypotension | ICU care, renal replacement therapy as bridge to transplant |
Severity guides urgency of liver transplantation evaluation and need for renal replacement therapy (RRT). In Kenya, early referral to transplant centres and use of affordable vasoconstrictor regimens (e.g., terlipressin where available, otherwise norepinephrine infusion) are critical. Monitoring includes daily creatinine, urine output, electrolytes, and hemodynamics.
Management
Immediate stabilisation
- Airway‑breathing‑circulation: give supplemental O₂ to keep SpO₂ > 94 %; treat any active GI bleed (vasopressin analogue, endoscopic control) before fluids.
- Volume assessment: avoid large crystalloid boluses; give a single albumin infusion (≈ 1 g/kg up to 100 g) to expand intravascular volume and improve renal perfusion.
- Infection screen: draw blood, urine and ascitic fluid for culture; start empiric broad‑spectrum antibiotics (e.g., a third‑generation cephalosporin) if infection is suspected.
Definitive treatment
| Goal | Agent / measure | Rationale |
|---|---|---|
| Splanchnic vasoconstriction | Terlipressin (vasopressin analogue) or midodrine + octreotide | Reduces portal inflow, raises systemic vascular resistance, improves renal blood flow. |
| Plasma expansion | Albumin (repeat 20–40 g daily) | Maintains oncotic pressure, supports response to vasoconstrictors. |
| Underlying liver disease | Transjugular intra‑hepatic portosystemic shunt (TIPS) if refractory ascites or variceal bleed; liver transplantation is definitive cure. | |
| Supportive care | Sodium restriction (≤ 2 g/day), diuretics only after volume expansion, avoid nephrotoxins (NSAIDs, aminoglycosides, contrast). | Prevent further renal insult. |
Monitoring & safety
- Vitals q1‑2 h (BP, HR, MAP > 65 mmHg).
- Urine output hourly; aim > 0.5 mL/kg/h.
- Serum creatinine, electrolytes, lactate q12 h until stable.
- Liver function & INR daily.
- Watch for ischemia (digital ischemia, myocardial ischemia) with vasopressors; stop if severe.
- If no improvement after 48 h of vasoconstrictor + albumin, reassess diagnosis and consider renal replacement therapy as bridge to transplant.
Contra‑indications / safety
- Terlipressin: contraindicated in uncontrolled cardiac disease, active coronary ischemia, severe peripheral vascular disease.
- Midodrine: avoid in severe supine hypertension.
- Albumin: caution in patients with severe pulmonary edema or heart failure.
Complications and prognosis
- Progressive renal failure → need for dialysis; mortality rises sharply once dialysis is required.
- Infections (spontaneous bacterial peritonitis, sepsis) are common triggers and worsen outcome.
- Hepatic encephalopathy may worsen with rapid fluid shifts.
- Electrolyte disturbances (hyponatraemia, hyperkalaemia) from diuretics or renal dysfunction.
- Ischemic complications from vasopressors (digital necrosis, myocardial ischemia).
Prognosis is poor without liver transplantation; median survival without transplant is < 2 months for type‑1 HRS and ≈ 6 months for type‑2. Early recognition and prompt therapy improve transplant candidacy.
High‑yield exam points
- Look‑alike conditions: Acute tubular necrosis, drug‑induced nephrotoxicity, cardiorenal syndrome, pre‑renal azotemia from hypovolaemia.
- Commonest wrong first step: Giving large crystalloid boluses before albumin; this worsens ascites and portal hypertension.
- Examiner bedside question: “Explain why the kidneys are failing despite a normal‑looking renal ultrasound.” (Answer: functional renal vasoconstriction secondary to severe splanchnic vasodilation.)
- Key diagnostic clue: Serum creatinine rise ≥ 0.3 mg/dL within 48 h in a cirrhotic patient with no other cause of renal injury, after albumin challenge.
- Management priority: Albumin + vasoconstrictor before any diuretic or dialysis.
Clinical case
Case: A 48‑year‑old man with known alcoholic cirrhosis (Child‑Pugh C) presents with increasing abdominal girth, mild confusion and oliguria for 24 h. BP 110/70 mmHg, HR 96 bpm, SpO₂ 96 % on room air. Abdomen: tense ascites, no tenderness. Labs: serum creatinine 2.2 mg/dL (baseline 0.9), Na⁺ 130 mmol/L, INR 2.1, bilirubin 4.5 mg/dL. Urine: bland sediment, no protein, no casts.
Questions
- What is the most appropriate next step?
Answer: Give albumin 100 g IV and start a vasopressin analogue (terlipressin) while arranging cultures and antibiotics if infection is suspected.
- Which feature helps differentiate HRS from acute tubular necrosis?
Answer: Absence of granular casts and a bland urine sediment despite rising creatinine, together with a recent albumin challenge that does not improve renal function.
- What definitive therapy should be discussed with the patient’s family?
Answer: Evaluation for liver transplantation; TIPS may be considered if transplant is not immediately available and the patient is a suitable candidate.
Practice questions
Question 1
A 55‑year‑old woman with hepatitis B cirrhosis (MELD 22) develops a rise in creatinine from 1.0 to 2.5 mg/dL over 48 h after a therapeutic paracentesis. She is euvolemic, urine sediment is clean. What is the next best step?
A. Start high‑dose furosemide
B. Give IV albumin then start terlipressin
C. Begin immediate haemodialysis
D. Order a renal biopsy
Answer: B. give IV albumin then start terlipressin – this is the standard initial therapy for HRS after volume expansion.
Question 2
Which of the following distinguishes type‑1 from type‑2 HRS?
A. Presence of ascites
B. Rate of creatinine rise
C. Requirement for dialysis
D. Underlying viral hepatitis
Answer: B. rate of creatinine rise – type‑1 is rapid (≥ 0.5 mg/dL in < 2 weeks).
Question 3
A patient with cirrhosis and HRS is started on terlipressin. After 24 h he develops painful, dusky fingertips. What is the most appropriate action?
A. Increase terlipressin dose
B. Add a calcium channel blocker
C. Stop terlipressin immediately
D. Switch to norepinephrine infusion
Answer: C. stop terlipressin immediately – peripheral ischemia is a recognized adverse effect.
Question 4
In a cirrhotic patient with suspected HRS, which investigation is least useful for confirming the diagnosis?
A. Urine sodium concentration
B. Fractional excretion of sodium
C. Renal Doppler ultrasound
D. Serum cystatin‑C
Answer: D. serum cystatin‑C – it does not add diagnostic value over standard labs in HRS.
Question 5
A 42‑year‑old man with sickle‑cell disease and chronic liver disease presents with oliguria and a creatinine of 2.8 mg/dL. Urine microscopy shows granular casts. Which diagnosis is most likely?
A. Hepatorenal syndrome
B. Acute tubular necrosis secondary to sickle‑cell crisis
C. Pre‑renal azotemia from diuretic overuse
D. Post‑renal obstruction
Answer: B. acute tubular necrosis – granular casts indicate intrinsic renal injury, not the functional failure seen in HRS.
Drafted with AI assistance from standard references and reviewed for structure. Check details against your lecture notes and the Kenya MoH guideline.